The present disclosure provides a method of producing a negative-strand RNA virus vector. The present disclosure specifically provides a method of producing a negative-strand RNA virus vector in the presence of a PKR inhibitory factor.

The present invention relates generally to the field of cancer therapy and oncolytic viruses. More particularly, it concerns armed, chimeric oncolytic viruses.

Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.

The present invention relates to a process for producing a cell which constitutively expresses cytotoxic virus poly-peptides (e.g. VSV G or Gag-Pol). The invention also provides plasmids/vectors and kits for use in the production of the cells. Furthermore, the invention provides a process for producing retroviruses using the cells of the invention.

The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.

Provided are compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided.

The present application discloses an oncolytic virus and a use thereof. The oncolytic virus comprises an M protein, in which the M protein includes amino acid substitution(s) at one or more of the following positions compared to an amino acid sequence set forth in SEQ ID NO 1: position 32, position 33, position 49, position 54, position 133, and position 225. Further disclosed are an expression vector for the oncolytic virus, a virus production cell capable of producing the oncolytic virus, and a pharmaceutical composition including the oncolytic virus, as well as a method for preparing the oncolytic virus, the expression vector for the oncolytic virus, the virus production cell, and/or the pharmaceutical composition, and a use of the oncolytic virus, the expression vector for the oncolytic virus, the virus production cell, and/or the pharmaceutical composition.

Provided are compounds of Formula III that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the antigen expression from a virus, gene or trans-gene expression from a virus, or virus protein expression in cells. Other uses, compositions and methods of using same are also provided. ##STR00001##

The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.

The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.